Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin stalk domain of group 1 Influenza A viruses is a highly conserved region of the hemagglutinin surface glycoprotein, which is critical for mediating fusion between the viral envelope and host endosomal membranes during infection[1][2][3][4][6]. Unlike the immunodominant and variable HA head (receptor-binding) domain, the stalk (or stem) region evolves slowly, is intolerant to major sequence changes, and contains conserved epitopes recognized by broadly neutralizing antibodies, making it an attractive target for universal influenza vaccines and therapeutics[1][2][3]. HA is a homotrimeric protein, and the stalk region is composed mainly of the HA2 subunit, which undergoes a dramatic conformational rearrangement at low pH—triggering fusion of viral and host membranes[2][3][4]. Targeting the stalk domain is considered a promising approach for the development of broadly protective influenza interventions[1][2][3][6].
Inhibition of membrane fusion by preventing conformational change in the stalk domain Neutralization of viral entry into host cells
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin stalk domain of group 1 Influenza A virus (HA stalk domain (group 1 IVA)).